Press Releases from PATH Diagnostics

Related program: Diagnostics

2023

WHO resolution on strengthening diagnostics capacity key for global progress

Brazil becomes the first malaria-endemic country to adopt single-dose tafenoquine and STANDARD G6PD Test for the treatment of relapsing Plasmodium vivax malaria

New panel of antibodies specific to SARS-CoV-2 variants available for vaccine researchers

Additional panel of antibodies available to support the development of affordable pneumococcal vaccines

Rapid diagnostic test data repository available to digital health developers supporting resource-constrained markets

2022

P. vivax malaria elimination efforts boosted by new agreement to expand access to G6PD testing

2021

New panel of antibodies available to support the development of affordable pneumococcal vaccines

PATH and Quansys Biosciences launch Q-Plex™ Human Environmental Enteric Dysfunction Diagnostic (11-Plex) to accelerate EED interventions

STANDARD G6PD Test receives regulatory approval by the Australian Therapeutic Goods Administration

PATH and The University of Queensland create custom proteins for malaria diagnostics

PATH supports partners to use environmental surveillance to monitor the presence of COVID-19

2020

PATH and Wondfo partner to develop a point-of-care rapid diagnostic test for G6PD deficiency

Washington COVID-19 Biorepository expands sample types to support early development of antibody assays

PATH and partners develop and market environmental surveillance tool for polio eradication

Washington COVID-19 biorepository supports global quest for affordable diagnostics

PATH-led study finds commercially available reference diagnostic detects malaria with whole blood sample